Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.62 |
| ▸ | DRD2 | P14416 | 8/20 | 0.62 |
| ▸ | DRD3 | P35462 | 8/20 | 0.62 |
| ▸ | DRD5 | P21918 | 8/20 | 0.62 |
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506557 | 1.00 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30299229 | 0.95 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL577378 | 0.95 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL4133301 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL30888625 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL20231604 | 0.93 | DRD1 (0.60) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL2607471 | 0.91 | DRD1 (0.62) | DRD1DRD2DRD3DRD5DRD4 | |
| Methylene Chloride SCHEMBL29094368 | 0.88 | DRD1 (0.55) | DRD1DRD2DRD3DRD5DRD4 | |
| SCHEMBL12077890 | 0.84 | DRD1 (0.51) | DRD1DRD2DRD3DRD5DRD4 | |
| Propylamine SCHEMBL9435187 | 0.83 | DRD2 (0.51) | DRD1DRD2DRD3DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| CN-118546047-B | Preparation method of cyclic chiral nitrile compound and application of cyclic chiral nitrile compound in preparation of ramelteon | 北京师范大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-118546047-A | Preparation method of cyclic chiral nitrile compound and application of cyclic chiral nitrile compound in preparation of ramelteon | 北京师范大学 | 2024-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | DRD1 4735/4885DRD2 4767/4885DRD3 4813/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | DRD1 4809/4885DRD2 4850/4885DRD3 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.